Steps Following Attainment of Remission: Discontinuation of Antidepressant Therapy.

No abstract is available for this paper.

• Publication year

  2001

• Venue

  The Primary Care Companion to the Journal Clinical Psychiatry

• Publication date

  2001-08-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.4088/PCC.V03N0404PMID 15014601PMCID PMC181183
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Paroxetine withdrawal syndrome.

  2003cited by this paper
• Delineating the Longitudinal Structure of Depressive Illness: Beyond Clinical Subtypes and Duration Thresholds1

  2000cited by this paper
• Separating discontinuation symptoms from relapse

  1999cited by this paper
• The importance of new antidepressants in the treatment of anxiety/depressive disorders.

  1999cited by this paper
• The Importance of New Antidepressants in the Treatment of Anxiety/Depressive Disorders

  1999cited by this paper
• Recurrence of first-episode geriatric depression after discontinuation of maintenance antidepressants.

  1999cited by this paper
• Clinical guidelines for establishing remission in patients with depression and anxiety.

  1999cited by this paper
• Discontinuation symptoms and SSRIs.

  1998cited by this paper
• Neurological channelopathies

  1998cited by this paper
• Withdrawal and rebound symptoms associated with abrupt discontinuation of venlafaxine.

  1998cited by this paper
• Remission and Residual Symptomatology in Major Depression

  1998cited by this paper
• Selective serotonin reuptake inhibitor discontinuation syndrome: a randomized clinical trial

  1998cited by this paper
• Fluvoxamine prevents recurrence of depression: results of a long‐term, double‐blind, placebo‐controlled study

  1998cited by this paper
• Implications of failing to achieve successful long-term maintenance treatment of recurrent unipolar major depression.

  1998cited by this paper
• Discontinuation of antidepressant therapy: emerging complications and their relevance.

  1998cited by this paper
• Neurotransmitter receptor and transporter binding profile of antidepressants and their metabolites.

  1997cited by this paper
• Antidepressant withdrawal reactions.

  1997cited by this paper
• Antidepressant discontinuation: a review of the literature.

  1997cited by this paper
• Clinical management of antidepressant discontinuation.

  1997cited by this paper
• Discontinuation symptoms after treatment with serotonin reuptake inhibitors: a literature review.

  1997cited by this paper
• Antidepressant Withdrawal Reactions

  1997cited by this paper
• Introduction/Antidepressant Discontinuation Syndrome: An Update on Serotonin Reuptake Inhibitors

  1997cited by this paper
• Serotonin reuptake inhibitor discontinuation syndrome: a hypothetical definition. Discontinuation Consensus panel.

  1997cited by this paper
• Possible biological mechanisms of the serotonin reuptake inhibitor discontinuation syndrome. Discontinuation Consensus Panel.

  1997cited by this paper
• Efficacy of venlafaxine and placebo during long‐term treatment of depression: a pooled analysis of relapse rates

  1996influential reference
• Open treatment of obsessive-compulsive disorder with venlafaxine: a series of ten cases.

  1996cited by this paper
• Paroxetine withdrawal syndrome.

  1995cited by this paper
• Residual symptoms after partial remission: an important outcome in depression

  1995cited by this paper
• Venlafaxine: measuring the onset of antidepressant action.

  1995cited by this paper
• Potential Withdrawal Syndrome Associated with Ssri Discontinuation

  1995cited by this paper
• Withdrawal Phenomena Associated with Antidepressant and Antipsychotic Agents

  1994cited by this paper
• Withdrawal reaction after sertraline discontinuation.

  1994cited by this paper
• Withdrawal reaction after sertraline discontinuation.

  1994cited by this paper
• Tricyclic Antidepressant Withdrawal Syndrome

  1993cited by this paper
• Tranylcypromine withdrawal phenomena.

  1993cited by this paper
• Time to recovery, chronicity, and levels of psychopathology in major depression. A 5-year prospective follow-up of 431 subjects.

  1992cited by this paper
• Biochemical, neurophysiological, and behavioral effects of Wy‐45,233 and other identified metabolites of the antidepressant venlafaxine

  1991cited by this paper
• Mania or hypomania after withdrawal from antidepressants.

  1990cited by this paper
• Three-year outcomes for maintenance therapies in recurrent depression.

  1990cited by this paper
• Mania or hypomania after withdrawal from antidepressants.

  1990cited by this paper
• Five-year outcome for maintenance therapies in recurrent depression.

  1990cited by this paper
• Heterocyclic antidepressant, monoamine oxidase inhibitor and neuroleptic withdrawal phenomena.

  1990cited by this paper
• Antidepressant withdrawal syndromes: phenomenology and pathophysiology

  1989cited by this paper
• Antidepressant withdrawal syndromes: phenomenology and pathophysiology.

  1989cited by this paper
• NIMH/NIH Consensus Development Conference statement. Mood disorders: pharmacologic prevention of recurrences. Consensus Development Panel.

  1985cited by this paper
• Antidepressant withdrawal phenomena.

  1984cited by this paper
• Predictors of relapse in major depressive disorder.

  1983cited by this paper

• Effect of psilocybin versus escitalopram on depression symptom severity in patients with moderate-to-severe major depressive disorder: observational 6-month follow-up of a phase 2, double-blind, randomised, controlled trial

  2024cites this paper
• Effects of discontinuation of serotonergic antidepressants prior to psilocybin therapy versus escitalopram for major depression

  2024cites this paper
• The sense of stopping migraine prophylaxis

  2023cites this paper
• A Randomized Clinical Trial Comparing Two Treatment Strategies, Evaluating the Meaningfulness of HAM-D Rating Scale in Patients With Major Depressive Disorder

  2022cites this paper
• Discontinuing antidepressants: Pearls and pitfalls

  2022cites this paper
• Feasibility of conducting a pilot randomized control trial of a psycho-education intervention in patients with a first episode psychosis in Uganda—A study protocol

  2022cites this paper
• Autobiographical memory style and clinical outcomes following mindfulness-based cognitive therapy (MBCT): An individual patient data meta-analysis.

  2021cites this paper
• What I have learnt from helping thousands of people taper off antidepressants and other psychotropic medications

  2021cites this paper
• The application of precision dosing in the use of sertraline throughout pregnancy for poor and ultrarapid metabolizer CYP 2C19 subjects: A virtual clinical trial pharmacokinetics study

  2021cites this paper
• Anxiety: An ignored aspect of Parkinson's disease lacking attention.

  2020cites this paper
• Brand versus generic: addressing non‐adherence, secular trends and non‐overlap

  2020cites this paper
• The effects of combining art psychotherapy with pharmacotherapy in treating major depressive disorder: Randomized control study

  2020cites this paper
• The development and tailoring of a peer support program for patients with diabetes mellitus and depression in a primary health care setting in Central Uganda

  2020cites this paper
• Brand vs. Generic: Addressing Non-Adherence, Secular Trends, and Non-Overlap

  2019influential citation
• Tapering of SSRI treatment to mitigate withdrawal symptoms.

  2019cites this paper
• Treatment Emergent Violence To Self And Others; A Literature Review of Neuropsychiatric Adverse Reactions For Antidepressant And Neuroleptic Psychiatric Drugs And General Medications.

  2019cites this paper
• Clinical Depression, Antidepressant Use, and Metabolic Syndrome-related Comorbidities among Canadian Older Adults: A Cross-sectional Analysis of Baseline Data from the Canadian Longitudinal Study of Aging

  2019influential citation
• Using Exercise To Treat Depression: An Analysis Of Clinical And Social Perspectives

  2019cites this paper
• An Active Inference Approach to Dissecting Reasons for Non-Adherence to Antidepressants

  2019cites this paper
• Relapse prevention in adults with major depressive disorder treated with vilazodone: a randomized, double-blind, placebo-controlled trial

  2018influential citation
• Exploration des représentations et des difficultés des médecins généralistes concernant l’arrêt des antidépresseurs dans le cadre d’un Épisode Dépressif Caractérisé de l’adulte de 18 à 75 ans

  2018cites this paper
• Antidepressant Discontinuation Syndrome

  2018cites this paper
• Prescription opioid epidemic in Pennsylvania: lessons from Medicare and Medicaid

  2018cites this paper
• Psychological and Physiological Influences on Multicultural and Nonverbal Assessment

  2017cites this paper
• Palpitations and Asthenia Associated with Venlafaxine in a CYP2D6 Poor Metabolizer and CYP2C19 Intermediate Metabolizer

  2017cites this paper
• Human amygdala engagement moderated by early life stress exposure is a biobehavioral target for predicting recovery on antidepressants

  2016cites this paper
• Long-term consequences of chronic fluoxetine exposure on the expression of myelination-related genes in the rat hippocampus

  2015cites this paper
• Long-term consequences of chronic fluoxetine exposure on the expression of myelination-related genes in the rat hippocampus

  2015cites this paper
• Characterization, treatment, and prevention of stress-induced psychopathology

  2014cites this paper
• Use of serotonergic antidepressants and bleeding risk in patients undergoing surgery.

  2014cites this paper
• Use of psychotropic drugs in dermatology: unique perspectives of a dermatologist and a psychiatrist.

  2013cites this paper
• Guidance for the Discontinuation or Switching of Antidepressant Therapies in Adults

  2013cites this paper
• Tricyclic Antidepressant Drug Interactions

  2012cites this paper
• Tapering antidepressants: is 3 months slow enough?

  2011cites this paper
• Antidepressants Discontinuation Syndrome

  2010cites this paper
• Answers to your questions about SSRIs.

  2010cites this paper
• Predictors of premature discontinuation of treatment in multiple disease states

  2009cites this paper
• Predictors of premature discontinuation of treatment in multiple disease states

  2009cites this paper
• Predictors of premature discontinuation of treatment in multiple disease states

  2009cites this paper
• Case 70. Depression

  2009cites this paper
• Antidepressant medications and other treatments of depressive disorders: a CINP Task Force report based on a review of evidence.

  2007cites this paper
• Antidepressant discontinuation syndrome.

  2006cites this paper
• Depression Management During Cancer Treatment

  2006cites this paper
• Tender Points as Predictors of Distress and the Pharmacologic Management of Fibromyalgia Syndrome

  2003cites this paper